Elevated cholesterol precursors other than cholestanol can also be a hallmark for CTX

Journal of Inherited Metabolic Disease

Volumn 31, Issue SUPPL. 2, 2008, Pages

  De Sain Van Der Velden, M G M ^a   Verrips, A ^b   Prinsen, B H C M T ^a   De Barse, M ^a   Berger, R ^a   Visser, G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

7 DEHYDROCHOLESTEROL; 7-DEHYDROCHOLESTEROL; BIOLOGICAL MARKER; CHENODEOXYCHOLIC ACID; CHOLESTA 5,8 DIEN 3 BETA OL; CHOLESTA-5,8-DIEN-3 BETA-OL; CHOLESTANOL; CHOLESTEROL; LANOSTEROL; LATHOSTEROL; SITOSTEROL; SITOSTEROL DERIVATIVE;

ARTICLE; BLOOD; CASE REPORT; CEREBROTENDINOUS XANTHOMATOSIS; CHILD; HUMAN; MALE; PREDICTIVE VALUE; PRESCHOOL CHILD; TIME; TREATMENT OUTCOME; UPREGULATION; URINE;

BIOLOGICAL MARKERS; CHENODEOXYCHOLIC ACID; CHILD; CHILD, PRESCHOOL; CHOLESTADIENOLS; CHOLESTANOL; CHOLESTEROL; DEHYDROCHOLESTEROLS; HUMANS; LANOSTEROL; MALE; PREDICTIVE VALUE OF TESTS; SITOSTEROLS; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION; XANTHOMATOSIS, CEREBROTENDINOUS;

EID: 84855609660     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-008-0963-1     Document Type: Article

References (24)

1. Batta AK, Shefer S, Batta M, et al (1985) Effect of chenodeoxycholic acid on biliary and urinary bile acids and bile alcohols in cerebrotendinous xanthomatosis; monitoring by high performance liquid chromatography. J Lipid Res 26:690-698.
2. Berginer VM, Salen G, Shefer S (1984) Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med 311:1649-1652.
3. Cali JJ, Hsieh CL, Francke U, et al (1991) Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem 266:7779-7783.
4. Carlson TL, Kottke BA (1989) Effect of 25-hydroxycholesterol and bile acids on the regulation of cholesterol metabolism in Hep G2 cells. Biochem J 264:241-247.
5. Hoshita T, Yasuhara M, Une M, et al (1980) Occurrence of bile alcohol glucuronides in bile of patients with cerebrotendinous xanthomatosis. J Lipid Res 21:1015-1021.
6. Krakowiak PA, Nwokoro NA, Wassif CA, et al (2000) Mutation analysis and description of sixteen RSH/Smith-Lemli-Opitz syndrome patients: polymerase chain reaction-based assays to simplify genotyping. Am J Med Genet 94:214-227. doi:10.1002/1096-8628 (20000918) 94:3<214::AID-AJMG7>3.0. CO;2-R.
7. Kuriyama M, Fujiyama J, Kasama T, et al (1991) High levels of plant sterols and cholesterol precursors in cerebrotendinous xanthomatosis. J Lipid Res 32:223-229.
8. Kuriyama M, Tokimura Y, Fujiyama J, et al (1994) Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use. J Neurol Sci 125:22-28. doi:10.1016/0022-510X (94) 90237-2.
9. Lee MH, Hazard S, Carpten JD, et al (2001) Fine-mapping, mutation analyses, and structural mapping of cerebrotendinous xanthomatosis in U. S.pedigrees. J Lipid Res 42:159-169.
10. Meiner V, Meiner Z, Reshef A, et al (1994) Cerebrotendinous xanthomatosis: molecular diagnosis enables presymptomatic detection of a treatable disease. Neurology 44:288-290.
11. Menkes JH, Schimschock JR, Swanson PD, et al (1968) Cerebrotendinous xanthomatosis. The storage of cholestanol within the nervous system. Arch Neurol 19:47-53.
12. Nakamura T, Matsuzawa Y, Takemura K, et al (1991) Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis. Metabolism 40:741-746. doi:10.1016/0026-0495 (91) 90094-D.
13. Nicolau G, Shefer S, Salen G, et al (1974) Determination of hepatic 3-hydroxy-3-methylglutaryl CoA reductase activity in man. J Lipid Res 15:94-98.
14. Nikkila K, Miettinen TA, Hockerstedt KV, et al (2005) Sterol parameters as markers of liver function in primary biliary cirrhosis before and after liver transplantation. Transpl Int 18:221-225. doi:10.1111/j.1432-2277.2004.00002.x.
15. Potkin BN, Hoeg JM, Connor WE, et al (1988) Aneurysmal coronary artery disease in cerebrotendinous xanthomatosis. Am J Cardiol 61:1150-1152. doi:10.1016/0002-9149 (88) 90155-5.
16. Salen G, Ahrens EH, Jr., Grundy SM, et al (1970) Metabolism of beta-sitosterol in man. J Clin Invest 49:952-967. doi:10.1172/JCI106315.
17. Salen G, Shefer S, Setoguchi T, et al (1975) Bile alcohol metabolism in man. Conversion of β-cholestane-α 7alpha, 12alpha, 25-tetrol to cholic acid. J Clin Invest 56:226-231. doi:10.1172/JCI108071.
18. Salen G, Shefer S, Tint GS, et al (1985) Biosynthesis of bile acids in cerebrotendinous xanthomatosis. Relationship of bile acid pool sizes and synthesis rates to hydroxylations at C-12, C-25, and C-26. J Clin Invest 76:744-751. doi:10.1172/JCI112030.
19. Salen G, Batta AK, Tint GS, et al (1994) Comparative effects of lovastatin and chenodeoxycholic acid on plasma cholestanol levels and abnormal bile acid metabolismincerebrotendinous xanthomatosis. Metabolism 43:1018-1022. doi:10.1016/0026-0495 (94) 90183-X.
20. Segev H, Reshef A, Clavey V, et al (1995) Premature termination codon at the sterol 27-hydroxylase gene causes cerebrotendinous xanthomatosis in a French family. Hum Genet 95:238-240. doi:10.1007/BF00209413.
21. Verrips A, Wevers RA, Van Engelen BG, et al (1999) Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis. Metabolism 48:233-238. doi:10.1016/S0026-0495 (99) 90040-9.
22. Verrips A, Hoefsloot LH, Steenbergen GC, et al (2000) Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain 123:908-919. doi:10.1093/brain/123.5.908.
23. Watts GF, Naoumova RP, Kelly JM, et al (1997) Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects. Am J Physiol 273:E462-E470.
24. Wolthers BG, Walrecht HT, Van Der Molen JC, et al (1991) Use of determinations of 7-lathosterol (5 alpha-cholest-7-en-3 beta-ol) and other cholesterol precursors in serum in the study and treatment of disturbances of sterol metabolism, particularly cerebrotendinous xanthomatosis. J Lipid Res 32:603-612.